Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Collegium Pharmaceutical, Inc. - Common Stock
(NQ:
COLL
)
29.66
-1.32 (-4.26%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 14, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Collegium Pharmaceutical, Inc. - Common Stock
< Previous
1
2
3
4
Next >
Demystifying Collegium Pharmaceutical: Insights From 4 Analyst Reviews
May 10, 2024
Via
Benzinga
COLL Stock Earnings: Collegium Pharmaceutical Beats EPS, Misses Revenue for Q1 2024
May 09, 2024
COLL stock results show that Collegium Pharmaceutical beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Collegium Reports First Quarter 2024 Financial Results
May 09, 2024
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium Announces CEO Transition
May 09, 2024
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium Announces Authorized Generic Agreement with Hikma Pharmaceuticals USA Inc. for Nucynta® and Nucynta® ER
April 29, 2024
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Critical Insights From Collegium Pharmaceutical Analyst Ratings: What You Need To Know
April 11, 2024
Via
Benzinga
Where Collegium Pharmaceutical Stands With Analysts
February 23, 2024
Via
Benzinga
Collegium to Report First Quarter 2024 Financial Results on May 9, 2024
April 25, 2024
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026
April 11, 2024
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium to Participate in 23rd Annual Needham Virtual Healthcare Conference
April 03, 2024
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Recap: Collegium Pharmaceutical Q4 Earnings
February 22, 2024
Via
Benzinga
Analyst Expectations For Collegium Pharmaceutical's Future
February 02, 2024
Via
Benzinga
Collegium Reports Record Fourth Quarter and Full-Year 2023 Financial Results
February 22, 2024
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium to Report Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024
February 08, 2024
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Why Collegium Pharmaceutical Shares Are Gaining Today
January 03, 2024
Collegium Pharmaceutical, Inc. (NASDAQ: COLL) today announced FY24 financial
Via
Benzinga
TDCX Receives Preliminary Non-binding Proposal Letter, Joins Pure Storage, Dyne Therapeutics And Other Big Stocks Moving Higher On Wednesday
January 03, 2024
U.S. stocks traded lower, with the Nasdaq Composite falling around 150 points on Wednesday. Shares of TDCX Inc. (NYSE: TDCX) rose sharply during Wednesday’s session after it disclosed receiving a...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Recap: Collegium Pharmaceutical Q3 Earnings
November 07, 2023
Via
Benzinga
Needham Maintains Buy Rating for Collegium Pharmaceutical: Here's What You Need To Know
August 25, 2023
Via
Benzinga
Collegium Provides 2024 Financial Guidance
January 03, 2024
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Appeals Court Upholds PTAB’s Finding of Invalidity of Purdue’s 961 Patent
November 27, 2023
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium Announces $25 Million Accelerated Share Repurchase Program
November 09, 2023
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium to Participate in Upcoming Investor Conferences
November 08, 2023
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium Reports Third Quarter 2023 Financial Results
November 07, 2023
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium to Report Third Quarter 2023 Financial Results on November 7, 2023
October 24, 2023
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium Announces 10 Poster Presentations at PAINWeek Conference 2023
August 28, 2023
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium Announces Extension of Nucynta Regulatory Exclusivity through July 2026
August 24, 2023
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium Announces $50 Million Accelerated Share Repurchase Program
August 07, 2023
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Atlassian, Universal Display, Booking, Dropbox And Other Big Stocks Moving Higher On Friday
August 04, 2023
U.S. stocks traded higher, with the Dow Jones gaining around 150 points on Friday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Collegium Reports Record 1H’23 Net Revenue of $280.3 Million, Up 35% Year-over-Year
August 03, 2023
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
Collegium to Report Second Quarter 2023 Financial Results on August 3, 2023
July 20, 2023
From
Collegium Pharmaceutical, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.